A 60-year-old man with poorly controlled type 2 diabetes mellitus is started on canagliflozin, a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor. Which of the following patterns of renal excretion changes would you expect after initiation of this medication?
Right-click options to strike through eliminated choices